
Opinion|Videos|May 7, 2024
Clinical Efficacy of Non-Statin Treatment Options in ASCVD
Focusing on PCSK9 inhibitors, inclisiran, and bempedoic acid, the panel compares treatment efficacy and outlines patient factors that influence treatment decisions.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Clinical Manifestations and Prognostic Impact of Anemia in Myelofibrosis
2
Trump Announces Pricing Deals With 9 Drugmakers, Expanding Most-Favored-Nation Drug Pricing Strategy
3
Understanding Myelofibrosis and the Central Role of JAK Pathway Dysregulation
4
More Dose Adjustments, Similar Outcomes: Ribociclib vs Palbociclib in Practice
5




































































































































































































